NCT03087760View on ClinicalTrials.gov

Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

Concurrent Pembrolizumab after proton reirradiation

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT03087760 - Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter